Influence of aging and comorbidity in the choice of disease-modifying treatments for multiple sclerosis in the Lazio region

被引：0

作者：

Pozzilli, C. ^{[1
,2
]}

Gasperini, C. ^{[3
]}

Bargagli, A. M. ^{[4
]}

Cascini, S. ^{[4
]}

Buttari, F. ^{[5
,6
]}

Centonze, D. ^{[5
,6
]}

Di Folco, M. ^{[1
]}

Francia, A. ^{[1
]}

Galgani, S. ^{[3
]}

Giuliani, M. ^{[2
]}

Colais, P. ^{[4
]}

Mirabella, M. ^{[7
]}

Nociti, V. ^{[7
,8
]}

Davoli, M. ^{[4
]}

机构：

[1] Univ Roma La Sapienza, Dept Neurol & Psichiatry, Rome, Italy

[2] Univ Roma La Sapienza, Multiple Sclerosis Ctr, S Andrea Hosp, Rome, Italy

[3] AOS Camillo Forlanini, Dept Neurosci, Rome, Italy

[4] Lazio Reg Hlth Serv, Dept Epidemiol, Rome, Italy

[5] Tor Vergata Univ & Hosp, MS Clin & Res Ctr, Rome, Italy

[6] IRCCS Ist Neurol Mediterraneo INM Neuromed, Pozzilli, Italy

[7] Catholic Univ, Dept Geriatr Neurosci & Orthoped, Rome, Italy

[8] Fdn Don C Gnocchi, Inst Neurorehabil, Milan, Italy

来源：

MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EP1478

引用

页码：771 / 772

页数：2

共 50 条

[31] Multiple sclerosis and disease-modifying therapies
Minen, Mia T.
Karceski, Steven
NEUROLOGY, 2011, 77 (04) : E26 - E26
[32] Disease-modifying therapy for multiple sclerosis
Holmoy, Trygve
Myhr, Kjell-Morten
Bo, Lars
Nygaard, Gro Owren
TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2021, 141 (08) : 723 - 726
[33] Disease-modifying therapy for multiple sclerosis
Klineova, Sylvia
Mitiku, Nesanet
Miller, Aaron E.
FUTURE NEUROLOGY, 2015, 10 (03) : 253 - 279
[34] Disease-modifying agents in multiple sclerosis
Coyle, P. K.
ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2009, 12 (04) : 273 - 282
[35] Disease-modifying therapies for multiple sclerosis
John R. Corboy
Douglas S. Goodin
Elliot M. Frohman
Current Treatment Options in Neurology, 2003, 5 (1) : 35 - 54
[36] Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab
Abbadessa, Gianmarco
Miele, Giuseppina
Cavalla, Paola
Valentino, Paola
Marfia, Girolama Alessandra
Vercellino, Marco
De Martino, Antonio
Simeon, Vittorio
Lavorgna, Luigi
Bonavita, Simona
JOURNAL OF NEUROIMMUNOLOGY, 2023, 378
[37] Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm
Giovannoni, Gavin
CURRENT OPINION IN NEUROLOGY, 2018, 31 (03) : 233 - 243
[38] Consensus recommendations on the use of follow-on disease-modifying treatments for multiple sclerosis
Brownlee, W. J.
Wolf, C.
Hartung, H. -P.
Dingermann, T.
Anshasi, N.
Trojano, M.
Selmaj, K.
Uitdehaag, B. M.
Tur, C.
Wuerfel, J.
Dallmann, G.
Witte, J.
Sintzel, M. B.
Bobrovnikova, O.
Cohen, J. A.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 362 - 363
[39] Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis
Lorena, Lorefice
Maristella, Pitzalis
Federica, Murgia
Giuseppe, Fenu
Luigi, Atzori
Eleonora, Cocco
FRONTIERS IN GENETICS, 2023, 14
[40] Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France
Lebrun, C.
Debouverie, M.
Jeannin, S.
Pittion-Vouyovitch, S.
Bayreuther, C.
Berthier, F.
MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (07) : 933 - 939

← 1 2 3 4 5 →